1.Clinical evaluation of treatment for diabetic foot with PTA and PTA combined cinepazide maleate
Jue WANG ; Ying-Sheng CHENG ; Yue-Qi ZHU ; Hua-Qiao TAN ; Jun-Gong ZHAN ;
Journal of Interventional Radiology 2006;0(12):-
Objective To investigate the clinical value for treatment of diabetic foot with PTA and PTA combined cinepazide maleate.Methods In 24 cases of diabetic associated vascular disease of lower limb,12 cases were treated with PTA and other 12 cases were treated with PTA combined einepazide maleate,We analysed and compared clinical effects before and after the procedure,together with 3 months follow up.Results In patients treated with PTA,the clinical symptom scores of posttreatment and follow-up decreased;ABI and TcPO_2 increased significantly.The clinical symptom score and ABI of follow-up remained,stable,but TcPO_2 decreased significantly.Control angiography showed improvement in degree of vascular stenosis and peripheral staining of 11 patients after treatment.The vascular patency remained in 12 patients and the peripheral staining decreased in 7 patients on follow-up.In patients treated with VIA combined cinepazide maleate,the clinical symptom score,ABI and TcPO_2 after treatment and on follow-up showed no signifcant changes compared with those in patients treated by PTA.F,Control angiography showed that the degree of vascular stenosis and peripheral staining were improved in 12 patients after treatment.The vascular pateney was maintained and peripheral staining was improved on follow-up.Before and after treatment,there were no significant differences in clinical symptom score.ABI and TcPO_2 between patients treated with PTA and PTA combined cinepazide maleate,however,there were significant differences in clinical symptom score and TcPO_2 on follow-up.Conclusion PTA can significantly improve clinical symptom of diabetic foot and the application of cinepazide maleate is a benefitial and necessary supplement.PTA combined cinepazide maleate can be taken as one of the conventional treatment plans for diabetic foot.(J Intervent Radiol,2007,16:811-815)
2.Clinical efficacy of electromagnetic navigation system in distal locking of tibia intramedullary nail
Han WU ; Xin-Zhong XU ; Wen-Dan CHENG ; Hao LÜ ; Jue-Hua JING
Journal of Regional Anatomy and Operative Surgery 2019;28(1):34-37
Objective To evaluate the clinical effect of electromagnetic navigation system to locate the distal locking screw of tibia intramedullary nail. Methods From February 2010 to December 2016, 79 cases of tibia shaft fractures requiring treatment with intramedullary nailing were selected and divided into the navigation group and free hand locking group according to intramedullary nail locking methods. Forty-four cases in navigation group used an electromagnetic navigation system to lock the distal end of the intramedullary nail,while 35 cases in free hand locking group used a free-hand technique. The intraoperative X-ray exposure time,distal locking time,healing time, and the success rate of one-time distal locking were recorded compared between two groups. Results The average time of diatal locking using electromagnetic navigation technology was less than that of the free hand locking group,and the exposure time of fluoroscopy was also reduced, the differences were significant(P < 0. 05). There was no difference in fracture healing time between the two groups(P > 0. 05), one-time success rate of navigation group was 100%,which was higher than 37. 34% of the free hand locking group, the difference was significant(P < 0. 05). Conclusion Compared with free hand technology, the advantage of using electromagnetic navigation system to lock the distal nail of tibia intramedullary nail is high efficiency, short locking time and no radiation.
3.Expression of NASG gene and its role in human nasopharyngeal homogenous tissue cells.
Zhong-qi LIU ; Yong-quan TIAN ; Cong PENG ; Yong-fang HU ; Ming ZHOU ; Jue OUYANG ; Xiao-ling LI ; Hua-ying LIU ; Bi-cheng ZHANG ; Gui-yuan LI
Chinese Medical Journal 2005;118(13):1076-1080
BACKGROUNDThe NASG gene has been confirmed as a tumor-suppressor gene candidate related to nasopharyngeal carcinoma (NPC) by previous studies. We further investigated the expression and the role of NASG in the homogeneous tissue cells by microdissecting the samples of tissue from human NPC, and introduced a new way to study the expression of specific genes in tumor tissue.
METHODSThe RNAlater reagent was used to preserve the samples of tissue from the nasopharynx of NPC patients. The samples were microdissected to harvest the homogeneous tissue cells and then total RNA was isolated from them. The antisense RNA (aRNA) was amplified from the total RNA by "in vitro transcription (IVT)". We investigated NASG expression in the homogeneous tumor cells of NPC (22 samples) and compared it with that in the pure epithelial pillar cells of normal nasopharyngeal (10 samples) by semi-quantitative reverse transcription-polymerase chain reaction (sqRT-PCR).
RESULTSThe high quality total RNA could be harvested from the microdissected homogeneous tissue cells of the nasopharynx, then sufficient aRNA was derived from it. NASG gene expression was identified using aRNA by sqRT-PCR and showed that there was significant difference between the average value of case groups and that of control group (t = -5.275, df = 30, P < 0.001). The NASG gene in the subgroups WHOII tended to express lower levels than those in the subgroup WHOIII although this difference was not statistically significant (t = -1.584, df = 20, P = 0.129 > 0.05).
CONCLUSIONSMicrodissection was an effective method to obtain the homogeneous tissue cells of nasopharyngeal tissue (including the samples of NPC and non-NPC) in our study. Sufficient aRNA from amplifying total RNA could be used in sqRT-PCR to analyse the expression of NASG in the pure tissue cells. NASG should be a tumor-suppression gene candidate regarding to NPC.
Adult ; Aged ; Female ; Genes, Tumor Suppressor ; Humans ; Male ; Microdissection ; Middle Aged ; Nasopharyngeal Neoplasms ; genetics ; Nasopharynx ; metabolism ; RNA ; analysis ; Reverse Transcriptase Polymerase Chain Reaction
4.Treatment of 116 patients with severe craniocerebral injury in basic-level hospital.
Qi-yun WU ; Cai-cheng WANG ; Xiao-hua HUANG ; Shu KANG ; Wen-guang SUN ; Ya-fei FENG ; Jue-zhong XIA
Chinese Journal of Traumatology 2003;6(3):190-192
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Child
;
China
;
Craniocerebral Trauma
;
diagnosis
;
therapy
;
Female
;
Hospitals, Community
;
Humans
;
Male
;
Middle Aged
5.Evaluation of the effects of standard rescue procedure on severe trauma treatment in china.
Xiao-Feng YIN ; Tian-Bing WANG ; Pei-Xun ZHANG ; Yu-Hui KOU ; Dian-Ying ZHANG ; Kai YU ; De-Cheng LYU ; Mao-Zheng LIU ; Dong-Sheng ZHOU ; Peng ZHANG ; Jue-Hua JING ; Wei-Wei GE ; Li Ying CAO ; Guo-Sheng WANG ; Shao-Jie DENG ; Weng-Hua LIU ; Mao ZHANG ; Yong-An XU ; Kun ZHANG ; Bing LI ; Wei WANG ; Zhong-Li GAO ; Cheng-La YI ; Bao-Guo JIANG ;
Chinese Medical Journal 2015;128(10):1301-1305
BACKGROUNDThis study aimed to evaluate the effects of standard rescue procedure (SRP) in improving severe trauma treatments in China.
METHODSThis study was conducted in 12 hospitals located in geographically and industrially different cities in China. A standard procedure on severe trauma rescue was established as a general rule for staff training and patient treatment. A regional network (system) efficiently integrating prehospital rescue, emergency room treatments, and hospital specialist treatments was built under the rule for information sharing and improving severe trauma treatments. Treatment outcomes were compared between before and 1 year after the implementation of the SRP.
RESULTSThe outcomes of a total of 74,615 and 12,051 trauma cases were collected from 12 hospitals before and after the implementation of the SRP. Implementation of the SRP led to efficient cooperation and information sharing of different treatment services. The emergency response time, prehospital transit time, emergency rescue time, consultation call time, and mortality rate of patients were 24.24 ± 4.32 min, 45.69 ± 3.89 min, 6.38 ± 1.05 min, 17.53 ± 0.72 min, and 33.82% ± 3.87% (n = 441), respectively, before the implementation of the standardization and significantly reduced to 10.11 ± 3.21 min, 22.39 ± 4.32 min, 3.26 ± 0.89 min, 3.45 ± 0.45 min, and 20.49% ± 3.11%, separately (n = 495, P < 0.05) after that.
CONCLUSIONSStaff training and SRP can significantly improve the efficiency of severe trauma treatments in China.
Adolescent ; Adult ; Aged ; Child ; Child, Preschool ; China ; Emergency Medical Services ; standards ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Wounds and Injuries ; Young Adult
6.Role of plasma C-reactive protein in predicting in-stent restenosis in patients with stable angina after coronary stenting.
Yan-lu XU ; Jian-jun LI ; Bo XU ; Cheng-gang ZHU ; Yue-jin YANG ; Ji-lin CHEN ; Shu-bin QIAO ; Jin-qing YUAN ; Xue-wen QIN ; Wei-hua MA ; Min YAO ; Hai-bo LIU ; Yong-jian WU ; Jue CHEN ; Shi-jie YOU ; Jun DAI ; Ran XIA ; Run-lin GAO
Chinese Medical Journal 2011;124(6):845-850
BACKGROUNDThe role of plasma high sensitivity C-reactive protein (hs-CRP) in in-stent restenosis (ISR) remains controversial. We investigated plasma hs-CRP level at both admission and follow-up in patients with stable angina (SA) after successful coronary stenting in order to clarify the predictive value of hs-CRP for ISR.
METHODSWe summarized 303 consecutive chronic SA patients with coronary drug-eluting stent (DES) implantation. The ISR was analyzed by quantitative coronary analysis (QCA) at a mean follow-up of 8 months, and the patients were divided into two groups according to the detected ISR as ISR group (n = 48) and non-ISR group (n = 255). Plasma hs-CRP was examined at both admission and 8-month follow-up in all patients, standard medication continued throughout the investigation period.
RESULTSQCA presented that 48 patients (15.8%) suffered from ISR at follow-up. The basic clinical characteristics were similar between the two groups, while plasma hs-CRP was higher in ISR group than that in non-ISR group at both admission and follow-up, P < 0.001 respectively. Multivariate regression analysis indicated that plasma hs-CRP level at either admission or follow-up could independently predict ISR occurrence (OR = 5.581, 95%CI 2.532-12.302, P < 0.001 and OR = 6.299, 95%CI 2.722-14.577, P < 0.001, respectively).
CONCLUSIONSOur data indicate that plasma hs-CRP level may independently predict ISR at both admission and follow-up in SA patients with coronary DES implantation, which implies that a chronic, sustained systemic inflammatory response might be involved in ISR pathogenesis.
Aged ; Angina Pectoris ; therapy ; C-Reactive Protein ; metabolism ; Coronary Restenosis ; blood ; therapy ; Female ; Humans ; Male ; Middle Aged ; Multivariate Analysis
7.MDR reversal activity of bromotetrandrine in vitro and in vivo.
Jian CHENG ; Jue-Qiong WANG ; Bao-An CHEN ; Feng GAO ; Wen-Lin XU ; Hui-Lin SHEN ; Jia-Hua DING ; Chong GAO ; Yun-Yu SUN ; Jun WANG ; Gang ZHAO ; Hui-Hui SONG ; Wen BAO ; Qian SUN ; Yong-Yuan DAI ; Xin-Chen SUN ; Hong-Yan CHENG ; Yu-Xia DENG ; Guo-Hong LI ; Ning-Na CHEN ; Li-Jie LIU ; Xue-Mei WANG
Journal of Experimental Hematology 2009;17(5):1183-1191
The present study was aimed to evaluate the MDR reversal activity of bromotetrandrine (BrTet) in vitro and in vivo. The inhibitory effects of adriamycin (ADM) used alone or in combination with BrTet or Tet on the proliferation of K562 and K562/A02 cells were evaluated by MTT assay. The ADM accumulation and the protein levels of P-glycoprotein (P-gp) were detected by flow cytometry. The mRNA levels of P-gp were determined by RT-PCR. The in vivo effect of BrTet and Tet was investigated by using nude mice grafted with sensitive human leukemia cell line K562 and MDR cell line K562/A02. The results showed that BrTet at 0.25, 0.5 and 1 micromol/L reversed the resistance to ADM in MDR K562/A02 cells in a dose-dependent manner. Flow cytometry suggested that BrTet significantly increased the intracellular accumulation of ADM in K562/A02 cells in a dose-dependent manner. BrTet also inhibited the overexpression of P-gp in K562/A02 cells, and down-regulated mdr1 expression. In nude mice bearing K562 xenografts on the left flank and K562/A02 xenografts on the right flank, intraperitoneal injection of 10 mg/kg BrTet significantly enhanced the antitumor activity of ADM against K562/A02 xenografts with inhibitory rates of 26.1%, while ADM alone inhibited the growth of K562/A02 xenografts only by 5.8%. No enhancement effect by BrTet was seen in K562 xenografts. It is concluded that BrTet shows significant MDR reversal activity in vitro and in vivo. Its activity may be related to the inhibition of P-gp overexpression and the increase intracellular accumulation of anticancer drugs. BrTet may be a promising-MDR modulator for eventual assessment in the clinic.
ATP Binding Cassette Transporter, Sub-Family B
;
ATP-Binding Cassette, Sub-Family B, Member 1
;
metabolism
;
Animals
;
Benzylisoquinolines
;
pharmacology
;
Drug Resistance, Multiple
;
drug effects
;
genetics
;
Drug Resistance, Neoplasm
;
drug effects
;
genetics
;
Female
;
Humans
;
K562 Cells
;
Mice
;
Mice, Inbred BALB C
;
Mice, Nude
;
Xenograft Model Antitumor Assays
8.Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patients with stable angina after stenting.
Yan-Lu XU ; Jian-Jun LI ; Bo XU ; Cheng-Gang ZHU ; Yue-Jin YANG ; Ji-Lin CHEN ; Shu-Bing QIAO ; Jin-Qing YUAN ; Xue-Wen QIN ; Wei-Hua MA ; Min YAO ; Hai-Bo LIU ; Yong-Jian WU ; Jue CHEN ; Shi-Jie YOU ; Jun DAI ; Ran XIA ; Run-Lin GAO
Chinese Medical Journal 2011;124(19):3022-3029
BACKGROUNDAlthough the role of C-reactive protein (CRP) in predicting rapid progression of atherosclerotic lesions has been intensively studied in unstable coronary artery disease, the data from patients with stable angina (SA) are largely absent. The present study evaluated a middle-size patient cohort who underwent percutaneous coronary intervention (PCI) with stent implantation and follow-up coronary angiography (CAG) and tested the hypothesis that increased plasma level of high-sensitive CRP would indicate rapid progression of de novo non-target coronary artery lesions in Chinese patients with SA.
METHODSThe study population comprised of 311 consecutive patients with chronic SA who underwent coronary stent implantation on initial admission and angiographic follow-up ((8.5 ± 1.2) months). Rapid angiographic progression of non-target lesion was angiographically assessed and the patients were classified into two groups according to whether the progression existed or not. The relation of plasma CRP levels to the progression of atherosclerosis was investigated.
RESULTSBaseline demographic, clinical, and angiographic data were similar in patients with and without progression. Rapid angiographic progression of non-target lesions occurred in 136 patients (43.7%) at follow-up: 77 had a ≥ 10% diameter reduction of pre-existing stenosis ≥ 50%, 26 had a ≥ 30% diameter reduction of a pre-existing stenosis < 50%, 64 developed a new lesion ≥ 30% in a previously normal segment, and 4 had progression of a lesion to total occlusion. Progression of non-target lesions was not associated with target lesion restenosis formation. High-sensitive CRP levels were markedly higher in progression patients than in non-progression ones (1.60 (0.80 - 3.46) mg/L vs. 0.96 (0.55 - 1.87) mg/L, P < 0.001). Multivariate regression analysis showed that plasma CRP independently predicted rapid angiographic progression of non-target lesions (P = 0.001). High-sensitive CRP levels above 1.32 mg/L (the cutoff value) were associated with a 3.5-fold increase in the risk of developing rapid atherosclerotic progression (OR = 3.497, 95%CI 2.045 - 5.980).
CONCLUSIONThe data confirmed and extended previous studies that plasma CRP might independently predict non-target lesion progression in patients with SA after stent implantation.
Angina Pectoris ; therapy ; C-Reactive Protein ; analysis ; Coronary Angiography ; Coronary Artery Disease ; blood ; pathology ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Stents
9.Effects of artesunate combined with bortezomib on apoptosis and autophagy of acute myeloid leukemia cells in vitro and its mechanism.
Lian Jie HU ; Tao JIANG ; Fu Jue WANG ; Shi Hua HUANG ; Xiao Min CHENG ; Yong Qian JIA
Chinese Journal of Hematology 2019;40(3):204-208
Objective: To investigate the effects of artesunate combined with bortezomib on the proliferation, apoptosis and autophagy of human acute myeloid leukemia cell lines MV4-11, and its mechanisms. Methods: MTT method was used to determine the anti-proliferation effect of different concentrations of artesunate, bortezomib and their combination on MV4-11 cells. The cell apoptosis were analyzed by flow cytometry. The expression of cleaved-Caspase-3, Bcl-2 family protein (Bcl-2, Mcl-1, Bim, Bax) and autophagy-related protein LC3B were assayed by Western blot. Results: Artesunate displayed a proliferation inhibition effect on MV4-11 with dose- and time-dependent manner, the IC(50) of artesunate on MV4-11 after 48 hours was 1.44 μg/ml. Bortezomib displayed a proliferation inhibition effect on MV4-11 with dose-dependent manner, the IC(50) of bortezomib on MV4-11 after 48 hours was 8.97 nmol/L. The combination of artesunate (0.75, 1.0 μg/ml) and Bortezomib (6, 8 nmol/L) showed higher inhibition on MV4-11 than artesunate or bortezomib alone in the same concentration gradient after 48 hours (P<0.05) . The cooperation index of the two drugs were all less than 1. The 48 h apoptotic rate of artesunate (1.5 μg/ml) on MV4-11 was (15.27±2.18) %, (19.85±3.23) % of bortezomib (8 nmol/L) , (81.67±5.96) % of combination of the two drugs, significantly higher than the single group (P<0.05) . When combination of the two drugs on MV4-11 after 24 hours, the levels of pro-apoptotic protein Bim and the cleaved activation of Caspase-3 and autophagy-related protein LC3B were up-regulated and the anti-apoptotic protein Bcl-2 expressions was down-regulated. Conclusion: Combination of artesunate with bortezomib shows a significant synergistic effects on proliferation, apoptosis and autophagy of MV4-11 cell lines, which may be associated with Bcl-2 family proteins expression.
Apoptosis
;
Artesunate
;
Autophagy
;
Bortezomib
;
Cell Line, Tumor
;
Cell Proliferation
;
Humans
;
Leukemia, Myeloid, Acute
10.Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Shi-Qi CHENG ; Heng-Yi FAN ; Xin XU ; Wei-Wei GAO ; Shi-Gang LV ; Min-Hua YE ; Miao-Jing WU ; Xiao-Li SHEN ; Zu-Jue CHENG ; Xin-Gen ZHU ; Yan ZHANG
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(4):558-563
Pituitary adenomas (PAs) are well known as a common intracranial benign tumor, and a portion of PAs are refractory to current therapeutic methods. ErbB receptors family signaling pathway regulates the expression of PAs activation associated gene. Inhibition of epidermal growth factor receptor (EGFR) can inhibit proliferation of PAs. Leucine-rich repeats and immunoglobulin-like domains protein 1 ( LRIG1), a negative mediated gene of ErbB receptors family, plays a role in many tumors. However, there are seldom researches about the functional role of LRIG1 in PAs. The aim of this study is to explore the potential effect of LRIG1 and its regulating mechanism in PAs. First, we investigated the role of LRIG1 in cell migration, invasion of PAs with transfected LRIG1 or control. Then, we explored its impact on cell proliferation and apoptosis of PAs in vivo. To study the regulating mechanism of LRIG1, we examined the expression of molecular factor of PI3K/AKT and Ras/Raf/ERK pathway using Western blotting in vitro and RT-PCR in vitro and in vivo. It was found that LRIG1 over-expression inhibited cell migration, invasion and proliferation, and promoted apoptosis of PAs in vivo and in vitro. Furthermore, LRIG1 suppressed the expression of signaling of PI3K/AKT and Ras/Raf/ERK pathways in PAs. LRIG1, as a negative mediated gene of tumor, can inhibit biological function of PAs via inhibiting PI3K/AKT and Ras/Raf/ERK pathways, and it might be a new target for gene therapy of PAs.
Animals
;
Apoptosis
;
genetics
;
Brain Neoplasms
;
genetics
;
pathology
;
Cell Line, Tumor
;
Cell Movement
;
genetics
;
Cell Proliferation
;
genetics
;
Female
;
Gene Expression Regulation, Neoplastic
;
Humans
;
MAP Kinase Signaling System
;
genetics
;
Membrane Glycoproteins
;
biosynthesis
;
genetics
;
Mice
;
Oncogene Protein v-akt
;
biosynthesis
;
Phosphatidylinositol 3-Kinases
;
genetics
;
Pituitary Neoplasms
;
genetics
;
pathology
;
Xenograft Model Antitumor Assays
;
raf Kinases
;
biosynthesis
;
genetics